Proleukin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The proleukin market size has grown strongly in recent years. It will grow from $1.24 million in 2025 to $1.32 million in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to approval for cystic fibrosis management, proven mucus thinning efficacy, chronic disease treatment need, hospital respiratory adoption, improved patient outcomes.

The proleukin market size is expected to see strong growth in the next few years. It will grow to $1.68 million in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising cf diagnosis rates, improved life expectancy of patients, expansion of homecare therapy use, growth of specialty pharmacies, continued respiratory innovation. Major trends in the forecast period include standard of care in cystic fibrosis treatment, long term use in mucus clearance therapy, home based nebulized treatment adoption, hospital and homecare integration, continued reliance on enzyme therapies.

The growing prevalence of cancer is expected to drive the growth of the Proleukin market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade nearby tissues and, if untreated, may metastasize to other parts of the body. The increasing prevalence of cancer is attributed to factors such as an aging population, improved detection methods, lifestyle changes, environmental exposures, and higher survival rates, all of which contribute to more people being diagnosed and living with cancer. Proleukin, a high-dose interleukin-2 therapy, helps cancer patients by stimulating the immune system’s natural ability to target and destroy cancer cells, offering a potential treatment option for advanced malignancies such as metastatic melanoma and renal cell carcinoma. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported an estimated 20 million new cancer cases and 9.7 million deaths in 2022, with projections suggesting a 77% increase to over 35 million new cases by 2050. Therefore, the rising prevalence of cancer is driving the Proleukin market.

Increasing research and development activities are also expected to support the growth of the Proleukin market. Research and development (R&D) includes systematic scientific investigations aimed at creating new products, improving existing ones, or developing new technologies and solutions. R&D spending is rising due to growing demand for innovation, technological advancements, and the need to address emerging global challenges across industries. Increased R&D benefits Proleukin by enhancing efficacy, exploring new cancer indications, improving delivery mechanisms, and potentially reducing side effects, thereby broadening its clinical utility and patient reach. For example, in February 2025, the National Center for Science and Engineering Statistics (NCSES), a US-based government agency, reported that U.S. R&D expenditures increased from $892 billion in 2022 to $940 billion in 2023, a $48 billion rise. Therefore, increasing R&D activities are driving the Proleukin market.

In May 2023, Iovance Biotherapeutics, a US-based biotechnology company focused on T-cell-based cancer immunotherapies, acquired Proleukin (aldesleukin) from Clinigen Limited for an undisclosed amount. This acquisition allows Iovance to enhance its T-cell immunotherapy platform by integrating Proleukin, a key immunotherapy agent, to improve the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies. This strengthens Iovance’s oncology pipeline and its position in the competitive cancer therapeutics market. Clinigen Group, a UK-based company, is the provider of Proleukin (aldesleukin).

Major companies operating in the proleukin market are Novartis Pharmaceuticals Corporation.

North America was the largest region in the proleukin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proleukin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proleukin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the pulmozyme market by increasing costs related to recombinant enzyme production and nebulizer compatible packaging materials. These impacts are most visible in hospital pharmacies and homecare supply chains across Europe and Asia Pacific. Higher import duties have contributed to increased therapy costs for chronic cystic fibrosis patients. Distribution logistics have also faced delays due to customs compliance. However, tariffs are encouraging regional biologics manufacturing and strengthening local respiratory therapy supply chains.

The proleukin market research report is one of a series of new reports that provides proleukin market statistics, including proleukin industry global market size, regional shares, competitors with a proleukin market share, detailed proleukin market segments, market trends and opportunities, and any further data you may need to thrive in the proleukin industry. This proleukin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Proleukin is the brand name for aldesleukin, a recombinant form of interleukin-2 (IL-2), a naturally occurring protein in the body. Classified as a biologic therapy, Proleukin is primarily used in oncology and immunotherapy. It works by stimulating the growth and activity of certain white blood cells (lymphocytes), enhancing the immune system’s ability to detect and attack cancer cells.

The main forms of Proleukin are injections, powders, and others. The injection is a liquid formulation of aldesleukin used to modulate the immune system. Its clinical indications include metastatic renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and other conditions, spanning therapeutic areas such as oncology and immunology. Proleukin is distributed through both online and offline channels and is administered in hospitals and pharmacies for adult and pediatric patients.

The proleukin market consists of sales of cancer vaccines, biosimilars, immune checkpoint inhibitors and adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.